N-{[3-(pyridin-3-yl)-1,2,4-oxadiazol-5-yl]methyl}ethene-1-sulfonamide
Structure Info
- Chemspace ID
- CSSB21332166468 (In-Stock Building Blocks)
- IUPAC Name
- N-{[3-(pyridin-3-yl)-1,2,4-oxadiazol-5-yl]methyl}ethene-1-sulfonamide
- Mol formula
- C10H10N4O3S
- Mol weight
- 266 Da
- Catalog Number(s)
- BBLS21332166468, EN300-54821550, bbls21332166468
- Copy structure to query editor
- SMILES
- INCHI
- INCHI key
- MOL
Properties
- LogP
- 0.42
- Heavy atoms count
- 18
- Rotatable bond count
- 4
- Number of rings
- 2
- Carbon bond saturation, Fsp3
- 0.1
- Polar surface area (Å)
- 98
- Hydrogen bond acceptors count
- 5
- Hydrogen bond donors count
- 1
![Chemical structure of N-{[3-(pyridin-3-yl)-1,2,4-oxadiazol-5-yl]methyl}ethene-1-sulfonamide (C10H10N4O3S) - CSSB21332166468](/st/structure/200/4055efb53e74047fa44d5844a6dae514/C%253DCS%2528%253DO%2529%2528%253DO%2529NCC1%253DNC%2528%253DNO1%2529C1%253DCN%253DCC%253DC1.png "C10H10N4O3S")
- Zoom the structure
- CSSB21332166468
Items Overall 8 items from 1 supplier
| Supplier | Lead time | Ships from | Purity | Pack | Price, $ | Qty |
|---|---|---|---|---|---|---|
| Enamine Ltd. | 15 days | Ukraine To: | 95 | 50 mg | 455.00 | |
| Enamine Ltd. | 15 days | Ukraine To: | 95 | 100 mg | 477.00 | |
| Enamine Ltd. | 15 days | Ukraine To: | 95 | 250 mg | 498.00 | |
| Enamine Ltd. | 15 days | Ukraine To: | 95 | 500 mg | 519.00 | |
| Enamine Ltd. | 15 days | Ukraine To: | 95 | 1 g | 541.00 | |
| Enamine Ltd. | 15 days | Ukraine To: | 95 | 2.5 g | 1,063.00 | |
| Enamine Ltd. | 15 days | Ukraine To: | 95 | 5 g | 1,572.00 | |
| Enamine Ltd. | 15 days | Ukraine To: | 95 | 10 g | 2,331.00 |
For a custom pack size or bulk
please drop us a line:Enquire
please drop us a line:Enquire
Similarity Analogs
![Chemical structure of N-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]ethene-1-sulfonamide - CSSB21332053700](/st/structure/200/5e8f8d928d1ae47fd723572d57934c78/C%253DCS%2528%253DO%2529%2528%253DO%2529NCC1%253DNC%2528%253DNO1%2529C1%253DCC%253DCC%253DC1.png)
![Chemical structure of N-{[3-(pyridin-4-yl)-1,2,4-oxadiazol-5-yl]methyl}ethene-1-sulfonamide - CSSB21332124581](/st/structure/200/0f1385c86fb5e87bbf9e633c4ba2a9d6/C%253DCS%2528%253DO%2529%2528%253DO%2529NCC1%253DNC%2528%253DNO1%2529C1%253DCC%253DNC%253DC1.png)
![Chemical structure of N-{[3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl]methyl}ethene-1-sulfonamide - CSSB21332053495](/st/structure/200/1de52fbaa7caaeded00a3aa92e8086e3/ClC1%253DCC%253DCC%2528%253DC1%2529C1%253DNOC%2528CNS%2528%253DO%2529%2528%253DO%2529C%253DC%2529%253DN1.png)
![Chemical structure of N-{[3-(3-fluorophenyl)-1,2,4-oxadiazol-5-yl]methyl}ethene-1-sulfonamide - CSSB21332126533](/st/structure/200/a1cb1be08cf8e5d7bbc85b01018681a6/FC1%253DCC%253DCC%2528%253DC1%2529C1%253DNOC%2528CNS%2528%253DO%2529%2528%253DO%2529C%253DC%2529%253DN1.png)
![Chemical structure of N-{[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]methyl}ethene-1-sulfonamide - CSSB21332125083](/st/structure/200/ccd58d814f5343ca0c6d456bbfbe1356/ClC1%253DCC%253DC%2528C%253DC1%2529C1%253DNOC%2528CNS%2528%253DO%2529%2528%253DO%2529C%253DC%2529%253DN1.png)
![Chemical structure of N-{[3-(3-bromophenyl)-1,2,4-oxadiazol-5-yl]methyl}ethene-1-sulfonamide - CSSB21332165891](/st/structure/200/fbb2c178d315d0a19d81564759549e6a/BrC1%253DCC%253DCC%2528%253DC1%2529C1%253DNOC%2528CNS%2528%253DO%2529%2528%253DO%2529C%253DC%2529%253DN1.png)
![Chemical structure of N-{[3-(pyridin-3-yl)-1,2,4-oxadiazol-5-yl]methyl}prop-2-enamide - CSSB01762230635](/st/structure/200/6f96de9dfed877266be1d4e9985b8ff6/C%253DCC%2528%253DO%2529NCC1%253DNC%2528%253DNO1%2529C1%253DCC%253DCN%253DC1.png)
